https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19329
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADOmeprazole by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of velpatasvir .
Possible decrease of clinical efficacy.
Monitor for clinical efficacy.
–
–
PPI doses should not exceed comparable to omeprazole 20 mg QD either dexlansoprazole 30 mg; esomeprazole 20 mg; lansoprazole 30 mg; pantoprazole 40 mg; rabeprazole 20 mg.
–
–
–
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
AUC |
Cmax |
3379 | 3379 |
---|---|
34 | 34 |
- | - |
400/100/100 mg | 400/100/100 mg |
x 1 | x 1 |
- 27%/- 54%/- 20% † | - 18%/- 51%/- 5% †† |
- 23%/- 57%/- 24% † | - 6%/- 51%/+ 8% †† |
3379 | 3379 |
---|---|
34 | 34 |
- | - |
20 mg | 20 mg |
QD * | QD ** |
Ref #3379 : * Omeprazole administred 2 hours before sofosbuvir/velpatasvir/voxilaprevir;
** Omeprazole administred 4 hours after sofosbuvir/velpatasvir/voxilaprevir;
† GS-331007 : AUC -3% and Cmax +27%;
†† GS-331007 : AUC -1% and Cmax +19%.